Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 This is to inform you that Glenmark Pharmaceuticals Limited will host an 'Investor Day' from 17:30 to 19:30 IST on Thursday, 17 November 2022, in Mumbai. The senior management team of Glenmark will be presenting the Company's growth plans to investors and research firms. The presentation material for the event will be disseminated to the Stock Exchange and uploaded on the Company's website closer to the event. This is for your information and records.
11-11-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2022

 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2022. The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.20 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com
11-11-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of Earnings Call slated for Monday, November 14, 2022 at 9:30 a.m. - 10:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
03-11-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 11, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2022 to November 13, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30, 2022.
02-11-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2022.

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 11, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2022 to November 13, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30, 2022.
02-11-2022

Glenmark Pharma gets US health regulator nod for generic medication

 Glenmark Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market Sodium Phenylbutyrate tablets, used in treating urea cycle disorders, in America. The company has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Horizon Therapeutics' Buphenyl, the Mumbai-based drug maker said in a statement. According to IQVIA sales data for 12-month period ended September 2022, Buphenyl had annual sales of around USD 8.7 million. Glenmark's current portfolio consists of 177 products authorised for distribution in the US marketplace and 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA.
02-11-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Sodium Phenylbutyrate Tablets USP, 500 mg
02-11-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Pharmaceuticals Launches Fingolimod Capsules, 0.5 Mg In The US

 Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US
31-10-2022
Bigul

Glenmark Pharma gets USFDA import alert on Baddi plant

 Facility contributes about 2% of FY22 total revenues
27-10-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Update On The Company''s Baddi (India) Facility

 Update on the Company''s Baddi (India) Facility
26-10-2022
Next Page
Close

Let's Open Free Demat Account